ArticleCancer immunology research2024

Nivolumab Reaches Brain Lesions in Patients with Recurrent Glioblastoma and Induces T-cell Activity and Upregulation of Checkpoint Pathways.

Signe K Skadborg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.